Lv41
560 积分 2023-12-02 加入
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
2小时前
已完结
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies
2小时前
已完结
Applications of SGLT2 inhibitors beyond glycaemic control
10天前
已完结
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
1个月前
已完结
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
1个月前
已完结
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2个月前
已完结
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2个月前
已完结
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
2个月前
已完结
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
2个月前
已完结
Diuretic Resistance in Heart Failure
4个月前
已完结
皖公网安备34019202002308
